Isoprostanes and Isofurans in Infertility and Assisted Reproduction: What Do We Know So Far?

A narrative review argues F2-isoprostanes and isofurans could be stable, reliable markers of reproductive oxidative damage — but admits the evidence base is thin

Journal: International Journal of Molecular Sciences | Published: 2026-05-23 | Type: Narrative Review | PMID: 42278246 Authors: Voros C et al. (Alexandra General Hospital & National and Kapodistrian University of Athens; one author at King's College Hospitals NHS, London) Funding/COI: Not listed

Summary

F2-isoprostanes and isofurans form when free radicals attack arachidonic acid in cell membranes — a process that happens in sperm, oocytes, and the follicular fluid surrounding eggs. This review synthesizes what's currently known about these lipid peroxidation byproducts in the context of infertility and ART outcomes. The authors' own framing tells you where things stand: they describe current understanding as "insufficient" and call for more research rather than reporting definitive findings.

Claims

• Elevated F2-isoprostane levels are associated with reduced sperm motility, compromised membrane integrity, and increased DNA fragmentation risk in male infertility
• Lipid peroxidation products have been detected in follicular fluid, with the review suggesting a link between oxidative imbalance, granulosa cell metabolism, and oocyte competency
• Isofurans — less studied than isoprostanes — form preferentially under high-oxygen conditions and may signal mitochondrial oxidative stress and disrupted cellular respiration
• Both markers arise from non-enzymatic peroxidation of arachidonic acid and are described as chemically stable, making them analytically attractive as in vivo biomarkers
• No specific effect sizes, odds ratios, or pooled statistics are reported — this is qualitative synthesis

Study Quality

This is a narrative review, not a systematic one. There is no PRISMA flow diagram, no stated inclusion/exclusion criteria, no database search strategy reported, and no quality assessment of included studies. That means the authors selected papers at their own discretion, with no structural protection against cherry-picking studies that support the isoprostane/isofuran hypothesis. The review covers both male and female reproductive biology, which is broad scope for this format.

The underlying primary literature being synthesized ranges from animal models to small clinical studies; the abstract does not disaggregate these, making it impossible to assess how much of the claim rests on human data versus rodent experiments. The MeSH terms include "Animals," confirming the review draws on non-human studies.

Red Flags

• Narrative review design: no search methodology, no quality appraisal of included studies — selection bias is structurally unconstrained
• No funding source and no conflict of interest declaration — unusual for a 10-author paper and a non-compliance with MDPI journal standards
• Large author list (10 authors) for a narrative review raises questions about contribution division
• Zero quantitative synthesis — no pooled estimates, no effect sizes, no sample sizes from cited studies appear in the abstract
• The authors explicitly state current knowledge is "insufficient" — the paper's own conclusion undercuts clinical utility claims
• Heavy use of associative language ("associated with," "suggesting a relationship") without effect magnitude

Strengths

• Isofurans are genuinely understudied compared to F2-isoprostanes; spotlighting them in reproductive biology is a legitimate contribution to the literature map
• Chemical stability of these biomarkers is a real analytical advantage over other oxidative stress markers that degrade rapidly ex vivo
• Covers both gamete types and the follicular microenvironment — more comprehensive than male-only or female-only oxidative stress reviews
• Published in a peer-reviewed journal indexed in PubMed

Verdict

This is a scene-setting review that tells you a field exists, not what's in it. The core argument — that isoprostanes and isofurans are promising reproductive biomarkers — is biologically plausible and the chemistry is sound, but the review provides no quantitative summary of how strongly these markers predict ART outcomes, what measurement thresholds appear in the literature, or how the human data compares to animal models. The missing funding/COI disclosure is a red flag for a multi-institutional paper. Worth scanning if you're building a reading list on oxidative stress biomarkers in ART; not worth citing as evidence that these markers have clinical utility.